Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial

Detalhes bibliográficos
Autor(a) principal: Rebelatto, Carmen Lúcia Kuniyoshi
Data de Publicação: 2022
Outros Autores: Senegaglia, Alexandra Cristina, Franck, Claudio Luciano, Daga, Debora Regina, Shigunov, Patrícia, Stimamiglio, Marco Augusto, Marsaro, Daniela Boscaro, Schaidt, Bruna, Micosky, Andressa, Azambuja, Ana Paula de, Leitão, Cleverson Alex, Petterle, Ricardo Rasmussen, Jamur, Valderez Ravaglio, Vaz, Isadora May, Mallmann, Antônio Paulo, Carraro Junior, Hipólito, Ditzel, Eduardo, Brofman, Paulo Roberto Slud, Correa, Alejandro
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/52571
Resumo: Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.
id CRUZ_ac060672924f15ad79658c1db8825860
oai_identifier_str oai:www.arca.fiocruz.br:icict/52571
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Rebelatto, Carmen Lúcia KuniyoshiSenegaglia, Alexandra CristinaFranck, Claudio LucianoDaga, Debora ReginaShigunov, PatríciaStimamiglio, Marco AugustoMarsaro, Daniela BoscaroSchaidt, BrunaMicosky, AndressaAzambuja, Ana Paula deLeitão, Cleverson AlexPetterle, Ricardo RasmussenJamur, Valderez RavaglioVaz, Isadora MayMallmann, Antônio PauloCarraro Junior, HipólitoDitzel, EduardoBrofman, Paulo Roberto SludCorrea, Alejandro2022-05-06T18:48:27Z2022-05-06T18:48:27Z2022REBELATTO, Carmen Lúcia Kuniyoshi et al. Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial. Stem Cell Research & Therapy, V. 13, n. 122, p. 1–22, 20221757-6512https://www.arca.fiocruz.br/handle/icict/5257110.1186/s13287-022-02796-1porBMCCOVID-19Postacute sequelaeTerapia CelularMesenchymal Stem CellsSubacute CareCell- and Tissue-Based TherapyCélulas Madre MesenquimatosasAtención SubagudaTratamiento Basado en Trasplante de Células y TejidosCellules souches mésenchymateusesSoins de suiteThérapie cellulaire et tissulaireCélulas-Tronco MesenquimaisCuidados Semi-IntensivosTerapia Baseada em Transplante de Células e TecidosSafety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlePontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Básica de Células Tronco. Curitiba, PR, Brasil.Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Básica de Células Tronco. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Universidade Federal do Paraná. Setor de Ciências da Saúde, Estatisitica. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Hospital e Maternidade Brígida, Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Hospital Nossa Senhora do Pilar. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Básica de Células Tronco. Curitiba, PR, Brasil.COVID-19 is a multisystem disease that presents acute and persistent symptoms, the postacute sequelae (PASC). Long-term symptoms may be due to consequences from organ or tissue injury caused by SARSCoV-2, associated clotting or infammatory processes during acute COVID-19. Various strategies are being chosen by clinicians to prevent severe cases of COVID-19; however, a single treatment would not be efcient in treating such a complex disease. Mesenchymal stromal cells (MSCs) are known for their immunomodulatory properties and regeneration ability; therefore, they are a promising tool for treating disorders involving immune dysregulation and extensive tissue damage, as is the case with COVID-19. This study aimed to assess the safety and explore the long-term efcacy of three intravenous doses of UC-MSCs (umbilical cord MSCs) as an adjunctive therapy in the recovery and postacute sequelae reduction caused by COVID-19. To our knowledge, this is one of the few reports that presents the longest follow-up after MSC treatment in COVID-19 patients. This was a phase I/II, prospective, single-center, randomized, double-blind, placebo-controlled clinical trial. Seventeen patients diagnosed with COVID-19 who require intensive care surveillance and invasive mechanical ventilation—critically ill patients—were included. The patient infusion was three doses of 5× 105 cells/kg UC-MSCs, with a dosing interval of 48 h (n=11) or placebo (n=6). The evaluations consisted of a clinical assessment, viral load, laboratory testing, including blood count, serologic, biochemical, cell subpopulation, cytokines and CT scan. The results revealed that in the UC-MSC group, there was a reduction in the levels of ferritin, IL-6 and MCP1- CCL2 on the fourteen day. In the second month, a decrease in the levels of reactive C-protein, D-dimer and neutrophils and an increase in the numbers of TCD3, TCD4 and NK lymphocytes were observed. A decrease in extension of lung damage was observed at the fourth month. The improvement in all these parameters was maintained until the end of patient follow-up.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83084https://www.arca.fiocruz.br/bitstream/icict/52571/1/license.txt783568c2893d2e25a99990b126be1772MD51ORIGINALs13287-022-0279OK.pdfs13287-022-0279OK.pdfapplication/pdf5220942https://www.arca.fiocruz.br/bitstream/icict/52571/2/s13287-022-0279OK.pdf616fce65779510c1e18ff103ef3350d8MD52icict/525712022-05-06 15:48:27.358oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-05-06T18:48:27Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
title Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
spellingShingle Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
Rebelatto, Carmen Lúcia Kuniyoshi
COVID-19
Postacute sequelae
Terapia Celular
Mesenchymal Stem Cells
Subacute Care
Cell- and Tissue-Based Therapy
Células Madre Mesenquimatosas
Atención Subaguda
Tratamiento Basado en Trasplante de Células y Tejidos
Cellules souches mésenchymateuses
Soins de suite
Thérapie cellulaire et tissulaire
Células-Tronco Mesenquimais
Cuidados Semi-Intensivos
Terapia Baseada em Transplante de Células e Tecidos
title_short Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
title_full Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
title_fullStr Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
title_full_unstemmed Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
title_sort Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
author Rebelatto, Carmen Lúcia Kuniyoshi
author_facet Rebelatto, Carmen Lúcia Kuniyoshi
Senegaglia, Alexandra Cristina
Franck, Claudio Luciano
Daga, Debora Regina
Shigunov, Patrícia
Stimamiglio, Marco Augusto
Marsaro, Daniela Boscaro
Schaidt, Bruna
Micosky, Andressa
Azambuja, Ana Paula de
Leitão, Cleverson Alex
Petterle, Ricardo Rasmussen
Jamur, Valderez Ravaglio
Vaz, Isadora May
Mallmann, Antônio Paulo
Carraro Junior, Hipólito
Ditzel, Eduardo
Brofman, Paulo Roberto Slud
Correa, Alejandro
author_role author
author2 Senegaglia, Alexandra Cristina
Franck, Claudio Luciano
Daga, Debora Regina
Shigunov, Patrícia
Stimamiglio, Marco Augusto
Marsaro, Daniela Boscaro
Schaidt, Bruna
Micosky, Andressa
Azambuja, Ana Paula de
Leitão, Cleverson Alex
Petterle, Ricardo Rasmussen
Jamur, Valderez Ravaglio
Vaz, Isadora May
Mallmann, Antônio Paulo
Carraro Junior, Hipólito
Ditzel, Eduardo
Brofman, Paulo Roberto Slud
Correa, Alejandro
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Rebelatto, Carmen Lúcia Kuniyoshi
Senegaglia, Alexandra Cristina
Franck, Claudio Luciano
Daga, Debora Regina
Shigunov, Patrícia
Stimamiglio, Marco Augusto
Marsaro, Daniela Boscaro
Schaidt, Bruna
Micosky, Andressa
Azambuja, Ana Paula de
Leitão, Cleverson Alex
Petterle, Ricardo Rasmussen
Jamur, Valderez Ravaglio
Vaz, Isadora May
Mallmann, Antônio Paulo
Carraro Junior, Hipólito
Ditzel, Eduardo
Brofman, Paulo Roberto Slud
Correa, Alejandro
dc.subject.other.pt_BR.fl_str_mv COVID-19
Postacute sequelae
Terapia Celular
topic COVID-19
Postacute sequelae
Terapia Celular
Mesenchymal Stem Cells
Subacute Care
Cell- and Tissue-Based Therapy
Células Madre Mesenquimatosas
Atención Subaguda
Tratamiento Basado en Trasplante de Células y Tejidos
Cellules souches mésenchymateuses
Soins de suite
Thérapie cellulaire et tissulaire
Células-Tronco Mesenquimais
Cuidados Semi-Intensivos
Terapia Baseada em Transplante de Células e Tecidos
dc.subject.en.pt_BR.fl_str_mv Mesenchymal Stem Cells
Subacute Care
Cell- and Tissue-Based Therapy
dc.subject.es.pt_BR.fl_str_mv Células Madre Mesenquimatosas
Atención Subaguda
Tratamiento Basado en Trasplante de Células y Tejidos
dc.subject.fr.pt_BR.fl_str_mv Cellules souches mésenchymateuses
Soins de suite
Thérapie cellulaire et tissulaire
dc.subject.decs.pt_BR.fl_str_mv Células-Tronco Mesenquimais
Cuidados Semi-Intensivos
Terapia Baseada em Transplante de Células e Tecidos
description Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.
publishDate 2022
dc.date.accessioned.fl_str_mv 2022-05-06T18:48:27Z
dc.date.available.fl_str_mv 2022-05-06T18:48:27Z
dc.date.issued.fl_str_mv 2022
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv REBELATTO, Carmen Lúcia Kuniyoshi et al. Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial. Stem Cell Research & Therapy, V. 13, n. 122, p. 1–22, 2022
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/52571
dc.identifier.issn.pt_BR.fl_str_mv 1757-6512
dc.identifier.doi.none.fl_str_mv 10.1186/s13287-022-02796-1
identifier_str_mv REBELATTO, Carmen Lúcia Kuniyoshi et al. Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial. Stem Cell Research & Therapy, V. 13, n. 122, p. 1–22, 2022
1757-6512
10.1186/s13287-022-02796-1
url https://www.arca.fiocruz.br/handle/icict/52571
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/52571/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/52571/2/s13287-022-0279OK.pdf
bitstream.checksum.fl_str_mv 783568c2893d2e25a99990b126be1772
616fce65779510c1e18ff103ef3350d8
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324935913897984